BioInvent International AB

At Swedish biotech BioInvent , early-stage data on two anti-tumor necrosis factor receptor 2 (TNFR2) antibodies are starting to show promise. Presenting at the annual Society for Immunotherapy for Ca

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Iktos Enters AI-Based Drug Design Pacts

Doing business via Zoom and Microsoft Teams has given European biotechs greater access to the investor community across the Atlantic, allowing companies more opportunities to tap into the considerable

BioInvent International AB has added to its healthy cash pile with a significant capital raise that puts the Swedish group in a strong position to advance its oncology pipeline led by the lymphoma ca